HUS1900048I1 - Anti-IL-23 antitestek - Google Patents

Anti-IL-23 antitestek

Info

Publication number
HUS1900048I1
HUS1900048I1 HUS1900048C HUS1900048I1 HU S1900048 I1 HUS1900048 I1 HU S1900048I1 HU S1900048 C HUS1900048 C HU S1900048C HU S1900048 I1 HUS1900048 I1 HU S1900048I1
Authority
HU
Hungary
Prior art keywords
antibodies
Prior art date
Application number
Other languages
English (en)
Original Assignee
Boehringer Ingelheim Int
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Boehringer Ingelheim Int filed Critical Boehringer Ingelheim Int
Publication of HUS1900048I1 publication Critical patent/HUS1900048I1/hu

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/24—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against cytokines, lymphokines or interferons
    • C07K16/244—Interleukins [IL]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/06—Antiasthmatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/06—Antipsoriatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
    • C12N15/113—Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides; Antisense DNA or RNA; Triplex- forming oligonucleotides; Catalytic nucleic acids, e.g. ribozymes; Nucleic acids used in co-suppression or gene silencing
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/34—Identification of a linear epitope shorter than 20 amino acid residues or of a conformational epitope defined by amino acid residues
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C07K2317/565—Complementarity determining region [CDR]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/94—Stability, e.g. half-life, pH, temperature or enzyme-resistance

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Genetics & Genomics (AREA)
  • Immunology (AREA)
  • Molecular Biology (AREA)
  • Biomedical Technology (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • General Engineering & Computer Science (AREA)
  • Biotechnology (AREA)
  • Wood Science & Technology (AREA)
  • Zoology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Pulmonology (AREA)
  • Microbiology (AREA)
  • Plant Pathology (AREA)
  • Physics & Mathematics (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Rheumatology (AREA)
  • Dermatology (AREA)
  • Hematology (AREA)
  • Obesity (AREA)
  • Neurosurgery (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Neurology (AREA)
  • Diabetes (AREA)
  • Pain & Pain Management (AREA)
HUS1900048 2010-11-04 2019-10-14 Anti-IL-23 antitestek HUS1900048I1 (hu)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US41015810P 2010-11-04 2010-11-04
US41195310P 2010-11-10 2010-11-10
US41259410P 2010-11-11 2010-11-11
US201161448785P 2011-03-03 2011-03-03
EP11781949.0A EP2635601B1 (en) 2010-11-04 2011-11-02 Anti-il-23 antibodies

Publications (1)

Publication Number Publication Date
HUS1900048I1 true HUS1900048I1 (hu) 2019-11-28

Family

ID=44936573

Family Applications (2)

Application Number Title Priority Date Filing Date
HUE11781949A HUE030916T2 (hu) 2010-11-04 2011-11-02 Anti-IL-23 antitestek
HUS1900048 HUS1900048I1 (hu) 2010-11-04 2019-10-14 Anti-IL-23 antitestek

Family Applications Before (1)

Application Number Title Priority Date Filing Date
HUE11781949A HUE030916T2 (hu) 2010-11-04 2011-11-02 Anti-IL-23 antitestek

Country Status (39)

Country Link
US (5) US8778346B2 (hu)
EP (4) EP3456740A1 (hu)
JP (3) JP6126532B2 (hu)
KR (2) KR101931591B1 (hu)
CN (2) CN107522784B (hu)
AP (1) AP3953A (hu)
AR (1) AR083747A1 (hu)
AU (3) AU2011323426B2 (hu)
BR (1) BR112013011065B1 (hu)
CA (2) CA2816950C (hu)
CO (1) CO6801628A2 (hu)
CY (2) CY1118014T1 (hu)
DK (1) DK2635601T3 (hu)
EA (2) EA030436B1 (hu)
EC (1) ECSP13012649A (hu)
ES (1) ES2593754T3 (hu)
GE (1) GEP201706733B (hu)
HK (1) HK1247940A1 (hu)
HR (1) HRP20161141T1 (hu)
HU (2) HUE030916T2 (hu)
IL (2) IL225648A (hu)
LT (2) LT2635601T (hu)
LU (1) LUC00132I2 (hu)
MA (1) MA34641B1 (hu)
ME (1) ME02499B (hu)
MX (3) MX2019000046A (hu)
MY (1) MY162791A (hu)
NL (1) NL301013I2 (hu)
NO (1) NO2019038I1 (hu)
NZ (1) NZ610592A (hu)
PE (1) PE20141162A1 (hu)
PL (1) PL2635601T3 (hu)
PT (1) PT2635601T (hu)
RS (1) RS55161B1 (hu)
SG (2) SG10201604605VA (hu)
SI (1) SI2635601T1 (hu)
TW (2) TWI653242B (hu)
UY (1) UY33703A (hu)
WO (1) WO2012061448A1 (hu)

Families Citing this family (32)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JO3244B1 (ar) 2009-10-26 2018-03-08 Amgen Inc بروتينات ربط مستضادات il – 23 البشرية
PT2635601T (pt) * 2010-11-04 2016-09-27 Boehringer Ingelheim Int Anticorpos anti-il-23
EP4039275A1 (en) * 2012-05-03 2022-08-10 Boehringer Ingelheim International GmbH Anti-il-23p19 antibodies
TWI636063B (zh) * 2013-03-08 2018-09-21 美國禮來大藥廠 結合ｉｌ－２３之抗體
KR20150128859A (ko) 2013-03-15 2015-11-18 암젠 인크 항-il23 항체를 사용하여 크론병을 치료하는 방법
WO2014149425A1 (en) 2013-03-15 2014-09-25 Amgen Inc. Methods for treating psoriasis using an anti-il-23 antibody
EP3172339A1 (en) * 2014-07-24 2017-05-31 Boehringer Ingelheim International GmbH Biomarkers useful in the treatment of il-23a related diseases
BR112017004169A2 (pt) 2014-09-03 2017-12-05 Boehringer Ingelheim Int composto direcionado à il-23a e ao tnf-alfa e usos do mesmo
CN107206081A (zh) * 2015-02-04 2017-09-26 勃林格殷格翰国际有限公司 治疗炎性疾病的方法
AU2016247921A1 (en) * 2015-04-14 2017-08-31 Boehringer Ingelheim International Gmbh Methods of treating diseases
US10280231B2 (en) * 2015-07-23 2019-05-07 Boehringer Ingelheim International Gmbh Compound targeting IL-23A and B-cell activating factor (BAFF) and uses thereof
KR20180063127A (ko) 2015-09-17 2018-06-11 암젠 인크 Il23 경로 바이오마커를 사용한, il23-길항제에 대한 임상 반응의 예측
TWI733695B (zh) * 2015-09-18 2021-07-21 德商百靈佳殷格翰國際股份有限公司 治療發炎性疾病之方法
AU2016348391A1 (en) * 2015-11-03 2018-05-17 Janssen Biotech, Inc. Antibodies specifically binding TIM-3 and their uses
KR20180096633A (ko) 2015-12-22 2018-08-29 암젠 인크 Il23-길항제에 대한 임상적 반응의 예측인자로서의 ccl20
MX2018012410A (es) 2016-04-15 2019-02-21 Boehringer Ingelheim Int Metodos para tratar enfermedades inflamatorias.
US20180105588A1 (en) * 2016-10-14 2018-04-19 Boehringer Ingelheim International Gmbh Methods of treating diseases
WO2019152989A1 (en) * 2018-02-05 2019-08-08 Tesaro, Inc Pediatric niraparib formulations and pediatric treatment methods
TWI744617B (zh) 2018-03-30 2021-11-01 美商美國禮來大藥廠 治療潰瘍性結腸炎之方法
SG11202100185VA (en) 2018-07-13 2021-02-25 Astrazeneca Collaboration Ventures Llc Treating ulcerative colitis with brazikumab
CN110818793A (zh) * 2018-08-14 2020-02-21 中山康方生物医药有限公司 抗IL-1β的抗体、其药物组合物及其用途
CN109810947B (zh) * 2019-01-18 2021-06-11 北京贝来生物科技有限公司 一种抑制Th17细胞活化的间充质干细胞及其制备方法和应用
MA55729A (fr) * 2019-04-15 2022-02-23 Sun Pharmaceutical Ind Ltd Procédés de traitement de sujets atteints d'arthrite psoriasique
US11396541B2 (en) 2019-12-20 2022-07-26 Novarock Biotherapeutics, Ltd. Anti-interleukin-23 P19 antibodies and methods of use thereof
CN111956606B (zh) * 2020-08-31 2021-05-14 江苏荃信生物医药有限公司 包含高浓度抗人白介素23单克隆抗体的低粘度液体制剂
TW202224702A (zh) 2020-09-10 2022-07-01 美商美國禮來大藥廠 治療性抗體調配物
JP2023544890A (ja) 2020-10-13 2023-10-25 ヤンセン バイオテツク，インコーポレーテツド 分化抗原群ｉｖ及び／又はｖｉｉｉを調節するための生物工学的に作製されたｔ細胞媒介免疫、材料及び他の方法
EP4347018A1 (en) 2021-05-28 2024-04-10 Eli Lilly and Company Anti-il-23p19 antibody regulation of genes involved in ulcerative colitis
KR20230009815A (ko) 2021-07-09 2023-01-17 연세대학교 산학협력단 Il-23에 의해 매개되는 질환의 중증도 예측용 조성물
WO2023056417A1 (en) 2021-09-30 2023-04-06 Eli Lilly And Company Anti-il-23p19 antibody regulation of genes involved in bowel urgency in ulcerative colitis
WO2024077113A1 (en) 2022-10-06 2024-04-11 Eli Lilly And Company Methods of treating fatigue in ulcerative colitis
CN117875575B (zh) * 2024-03-12 2024-05-28 中国电子科技集团公司第二十九研究所 一种基于混合仿生算法的干扰资源分配方法

Family Cites Families (119)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4179337A (en) 1973-07-20 1979-12-18 Davis Frank F Non-immunogenic polypeptides
US4275149A (en) 1978-11-24 1981-06-23 Syva Company Macromolecular environment control in specific receptor assays
US4318980A (en) 1978-04-10 1982-03-09 Miles Laboratories, Inc. Heterogenous specific binding assay employing a cycling reactant as label
JPS6023084B2 (ja) 1979-07-11 1985-06-05 味の素株式会社 代用血液
WO1981001145A1 (en) 1979-10-18 1981-04-30 Univ Illinois Hydrolytic enzyme-activatible pro-drugs
US4419446A (en) 1980-12-31 1983-12-06 The United States Of America As Represented By The Department Of Health And Human Services Recombinant DNA process utilizing a papilloma virus DNA as a vector
US4485045A (en) 1981-07-06 1984-11-27 Research Corporation Synthetic phosphatidyl cholines useful in forming liposomes
NZ201705A (en) 1981-08-31 1986-03-14 Genentech Inc Recombinant dna method for production of hepatitis b surface antigen in yeast
US4640835A (en) 1981-10-30 1987-02-03 Nippon Chemiphar Company, Ltd. Plasminogen activator derivatives
US4741900A (en) 1982-11-16 1988-05-03 Cytogen Corporation Antibody-metal ion complexes
US4601978A (en) 1982-11-24 1986-07-22 The Regents Of The University Of California Mammalian metallothionein promoter system
US4560655A (en) 1982-12-16 1985-12-24 Immunex Corporation Serum-free cell culture medium and process for making same
US4657866A (en) 1982-12-21 1987-04-14 Sudhir Kumar Serum-free, synthetic, completely chemically defined tissue culture media
US4816567A (en) 1983-04-08 1989-03-28 Genentech, Inc. Recombinant immunoglobin preparations
DD266710A3 (de) 1983-06-06 1989-04-12 Ve Forschungszentrum Biotechnologie Verfahren zur biotechnischen Herstellung van alkalischer Phosphatase
US4544545A (en) 1983-06-20 1985-10-01 Trustees University Of Massachusetts Liposomes containing modified cholesterol for organ targeting
US4767704A (en) 1983-10-07 1988-08-30 Columbia University In The City Of New York Protein-free culture medium
US4496689A (en) 1983-12-27 1985-01-29 Miles Laboratories, Inc. Covalently attached complex of alpha-1-proteinase inhibitor with a water soluble polymer
US4965199A (en) 1984-04-20 1990-10-23 Genentech, Inc. Preparation of functional human factor VIII in mammalian cells using methotrexate based selection
US4879231A (en) 1984-10-30 1989-11-07 Phillips Petroleum Company Transformation of yeasts of the genus pichia
US4737456A (en) 1985-05-09 1988-04-12 Syntex (U.S.A.) Inc. Reducing interference in ligand-receptor binding assays
DE3675588D1 (de) 1985-06-19 1990-12-20 Ajinomoto Kk Haemoglobin, das an ein poly(alkenylenoxid) gebunden ist.
GB8516415D0 (en) 1985-06-28 1985-07-31 Celltech Ltd Culture of animal cells
US4927762A (en) 1986-04-01 1990-05-22 Cell Enterprises, Inc. Cell culture medium with antioxidant
GB8610600D0 (en) 1986-04-30 1986-06-04 Novo Industri As Transformation of trichoderma
US4791192A (en) 1986-06-26 1988-12-13 Takeda Chemical Industries, Ltd. Chemically modified protein with polyethyleneglycol
GB8705477D0 (en) 1987-03-09 1987-04-15 Carlton Med Prod Drug delivery systems
US4975278A (en) 1988-02-26 1990-12-04 Bristol-Myers Company Antibody-enzyme conjugates in combination with prodrugs for the delivery of cytotoxic agents to tumor cells
ATE135397T1 (de) 1988-09-23 1996-03-15 Cetus Oncology Corp Zellenzuchtmedium für erhöhtes zellenwachstum, zur erhöhung der langlebigkeit und expression der produkte
FR2646437B1 (fr) 1989-04-28 1991-08-30 Transgene Sa Nouvelles sequences d'adn, leur application en tant que sequence codant pour un peptide signal pour la secretion de proteines matures par des levures recombinantes, cassettes d'expression, levures transformees et procede de preparation de proteines correspondant
EP0402226A1 (en) 1989-06-06 1990-12-12 Institut National De La Recherche Agronomique Transformation vectors for yeast yarrowia
US5013556A (en) 1989-10-20 1991-05-07 Liposome Technology, Inc. Liposomes with enhanced circulation time
US5122469A (en) 1990-10-03 1992-06-16 Genentech, Inc. Method for culturing Chinese hamster ovary cells to improve production of recombinant proteins
US6407213B1 (en) 1991-06-14 2002-06-18 Genentech, Inc. Method for making humanized antibodies
WO1994004679A1 (en) 1991-06-14 1994-03-03 Genentech, Inc. Method for making humanized antibodies
WO1994004188A1 (en) 1992-08-21 1994-03-03 Genentech, Inc. Method for treating an lfa-1-mediated disorder
DK0669836T3 (da) 1992-11-13 1996-10-14 Idec Pharma Corp Terapeutisk anvendelse af kimære og radioaktivt mærkede antistoffer og humant B-lymfocytbegrænset differentieringsantigen til behandling af B-cellelymfom
US6096871A (en) 1995-04-14 2000-08-01 Genentech, Inc. Polypeptides altered to contain an epitope from the Fc region of an IgG molecule for increased half-life
US6037454A (en) 1996-11-27 2000-03-14 Genentech, Inc. Humanized anti-CD11a antibodies
US5888809A (en) 1997-05-01 1999-03-30 Icos Corporation Hamster EF-1α transcriptional regulatory DNA
US6060284A (en) 1997-07-25 2000-05-09 Schering Corporation DNA encoding interleukin-B30
PE20000183A1 (es) 1997-07-25 2000-03-11 Schering Corp Citoquinas de mamiferos y reactivos relacionados
WO1999040195A1 (en) 1998-02-06 1999-08-12 Schering Corporation Mammalian receptor proteins; related reagents and methods
ATE474849T1 (de) 1998-04-14 2010-08-15 Chugai Pharmaceutical Co Ltd Neues cytokinartiges protein
DE60038304T3 (de) 1999-09-09 2017-04-06 Merck Sharp & Dohme Corp. Interleukin-12 p40 und interleukin-b30. kombinationen davon. antikörper. verwendungen in pharmazeutische zusammensetzungen
US7090847B1 (en) 1999-09-09 2006-08-15 Schering Corporation Mammalian cytokines; related reagents and methods
MXPA02011081A (es) 2000-05-10 2003-03-10 Schering Corp Proteinas de subunidad de receptor de citocina de mamifero, reactivos y metodos relacionados.
US7422743B2 (en) 2000-05-10 2008-09-09 Schering Corporation Mammalian receptor protein DCRS5;methods of treatment
JPWO2003034818A1 (ja) 2001-10-24 2005-02-10 中外製薬株式会社 Ｓｇｒｆ遺伝子改変非ヒト動物
IL161677A0 (en) 2001-11-08 2004-09-27 Protein Design Labs Stable liquid pharmaceutical formulation of igg antibodies
DE60328823D1 (de) 2002-10-30 2009-09-24 Genentech Inc Hemmung von il-17 produktion
ATE515514T1 (de) 2002-12-23 2011-07-15 Schering Corp Verwendungen von säuger-cytokin il-23 ; verwandte reagenzien
WO2004071517A2 (en) 2003-02-06 2004-08-26 Schering Corporation Uses of il-23 related reagents
ES2330220T3 (es) 2003-03-10 2009-12-07 Schering Corporation Usos de antagonistas de il-23; reactivos relacionados.
US7413894B2 (en) 2003-07-01 2008-08-19 University Of Virginia Patent Foundation TAG-1 and TAG-2 proteins and uses thereof
ATE447412T1 (de) 2003-11-04 2009-11-15 Novartis Vaccines & Diagnostic Antagonist-anti-cd40-monoklonale antikörper und anwendungsverfahren
US8277810B2 (en) 2003-11-04 2012-10-02 Novartis Vaccines & Diagnostics, Inc. Antagonist anti-CD40 antibodies
US20070218060A1 (en) 2003-11-04 2007-09-20 Chiron Corporation Use of Antagonist Anti-Cd40 Monoclonal Antibodies for Treatment of Multiple Myeloma
US20050100965A1 (en) 2003-11-12 2005-05-12 Tariq Ghayur IL-18 binding proteins
EP1901768B1 (en) 2004-02-17 2011-11-16 Schering Corporation Methods of modulating il-23 activity; related reagents
US7501247B2 (en) 2004-05-03 2009-03-10 Schering Corporation Method of treating skin inflammation
US20050287593A1 (en) 2004-05-03 2005-12-29 Schering Corporation Use of cytokine expression to predict skin inflammation; methods of treatment
EP1799700A4 (en) * 2004-09-27 2009-02-11 Centocor Inc SRAGE MIMETIC BODIES, COMPOSITIONS, PROCESSES AND USES
JO3000B1 (ar) 2004-10-20 2016-09-05 Genentech Inc مركبات أجسام مضادة .
WO2006068987A2 (en) 2004-12-20 2006-06-29 Schering Corporation Uses of il-23 antagonists in the treatment of diabetes mellitus
JP2009501006A (ja) 2005-06-30 2009-01-15 セントカー・インコーポレーテツド 抗ｉｌ−２３抗体、組成物、方法および用途
US20090142855A1 (en) 2005-06-30 2009-06-04 Wei Tang Polynucleotides and Polypeptides of the IL-12 Family of Cytokines
CN101248088A (zh) * 2005-08-25 2008-08-20 伊莱利利公司 抗il-23抗体
US7872102B2 (en) 2005-08-25 2011-01-18 Eli Lilly And Company Anti-IL-23 antibodies
SG165322A1 (en) * 2005-08-31 2010-10-28 Schering Corp Engineered anti-il-23 antibodies
PT1933869E (pt) 2005-09-01 2009-12-24 Schering Corp Utilização de antagonistas de il-23 e il-para tratar a doença inflamatória ocular auto-imune
EP1977007A4 (en) 2005-12-28 2009-11-11 Centocor Ortho Biotech Inc MARKERS AND METHOD FOR THE ASSESSMENT AND TREATMENT OF PSORIASIS AND RELATED DISEASES
PL1971366T3 (pl) 2005-12-29 2015-01-30 Janssen Biotech Inc Ludzkie przeciwciała skierowane przeciw IL-23, kompozycje, sposoby i zastosowanie
US7910703B2 (en) 2006-03-10 2011-03-22 Zymogenetics, Inc. Antagonists to IL-17A, IL-17F, and IL-23P19 and methods of use
US20080311043A1 (en) 2006-06-08 2008-12-18 Hoffman Rebecca S Uses and compositions for treatment of psoriatic arthritis
WO2007147019A2 (en) 2006-06-13 2007-12-21 Zymogenetics, Inc. Il-17 and il-23 antagonists and methods of using the same
EP2029171A1 (en) 2006-06-19 2009-03-04 Wyeth a Corporation of the State of Delaware Methods of modulating il-22 and il-17
AR064826A1 (es) 2007-01-09 2009-04-29 Wyeth Corp Formulaciones de anticuerpos anti-il-13 y usos de los mismos. dispositivos, parche y jeringa
TWI426918B (zh) 2007-02-12 2014-02-21 Merck Sharp & Dohme Ｉｌ-２３拮抗劑於治療感染之用途
MX2009008769A (es) 2007-02-16 2009-08-25 Wyeth Corp Formulaciones de proteina que contienen sorbitol.
HUE042172T2 (hu) 2007-02-23 2019-06-28 Merck Sharp & Dohme Genetikailag elõállított anti-il-23P19 antitestek
JP2010518858A (ja) 2007-02-23 2010-06-03 シェーリング コーポレイション 操作された抗−ｉｌ−２３ｐ１９抗体
JP5337055B2 (ja) 2007-02-28 2013-11-06 メルク・シャープ・アンド・ドーム・コーポレーション 免疫性障害の処置のための組合せ治療
CA2698357C (en) 2007-09-04 2017-06-06 The Government Of The United States Of America, As Represented By The Secretary Of The Department Of Health And Human Services Deletions in domain ii of pseudomonas exotoxin a that reduce non-specific toxicity
AR068723A1 (es) 2007-10-05 2009-12-02 Glaxo Group Ltd Proteina que se une a antigenos que se une a il-23 humana y sus usos
WO2009053493A1 (en) 2007-10-26 2009-04-30 Galderma Research & Development Non-invasive method to perform skin inflammatory disease pharmaco-genomic studies and diagnosis method thereof
CA2607771A1 (en) 2007-11-01 2009-05-01 Her Majesty The Queen In Right Of Canada As Represented By The Minister Of National Defence Humanized anti-venezuelan equine encephalitis virus recombinant antibody
US8420081B2 (en) 2007-11-30 2013-04-16 Abbvie, Inc. Antibody formulations and methods of making same
WO2009082624A2 (en) 2007-12-10 2009-07-02 Zymogenetics, Inc. Antagonists of il-17a, il-17f, and il-23 and methods of using the same
AR073060A1 (es) 2008-08-14 2010-10-13 Arana Therapeutic Ltd Anticuerpos anti-il-12/il-23
MX2011002159A (es) 2008-08-27 2011-03-29 Schering Corp Formulaciones liofilizadas de anticuerpos anti-interleucina-23p19 construidos por ingenieria.
US8420089B2 (en) 2008-11-25 2013-04-16 Alderbio Holdings Llc Antagonists of IL-6 to raise albumin and/or lower CRP
WO2010115786A1 (en) 2009-04-01 2010-10-14 Glaxo Group Limited Anti-il-23 immunoglobulins
WO2010115092A2 (en) 2009-04-02 2010-10-07 The Johns Hopkins University Compositions and methods for treating or preventing inflammatory bowel disease and colon cancer
WO2011011797A2 (en) 2009-07-24 2011-01-27 The Board Of Trustees Of The Leland Stanford Junior University Cytokine compositions and methods of use thereof
JO3244B1 (ar) 2009-10-26 2018-03-08 Amgen Inc بروتينات ربط مستضادات il – 23 البشرية
EP2504030A4 (en) 2009-11-24 2013-06-26 Alderbio Holdings Llc IL-6 ANTAGONISTS FOR INCREASING ALBUMIN AND / OR REDUCING CRP
WO2011069000A2 (en) 2009-12-02 2011-06-09 Spartek Medical, Inc. Low profile spinal prosthesis incorporating a bone anchor having a deflectable post and a compound spinal rod
GB201013975D0 (en) 2010-08-20 2010-10-06 Imp Innovations Ltd Method of treating desease
EA201270713A1 (ru) 2010-02-18 2013-01-30 Бристол-Майерс Сквибб Компани Белки на основе фибронектина с каркасными доменами, которые связывают ил-23
JP2013520476A (ja) 2010-02-26 2013-06-06 ノヴォ ノルディスク アー／エス 安定な抗体含有組成物
JP5937523B2 (ja) 2010-03-01 2016-06-22 サイトダイン インコーポレイテッドＣｙｔｏＤｙｎ， Ｉｎｃ． 濃縮されたタンパク質製剤およびその使用
CA2798742A1 (en) 2010-06-15 2011-12-22 Celgene Corporation Biomarkers for the treatment of psoriasis
US20110311527A1 (en) 2010-06-16 2011-12-22 Allergan, Inc. IL23p19 ANTIBODY INHIBITOR FOR TREATING OCULAR AND OTHER CONDITIONS
US9127057B2 (en) 2010-07-20 2015-09-08 Teva Pharmaceuticals Ausralia Pty Ltd Anti-IL-23 heterodimer specific antibodies
CN103261222B (zh) 2010-09-10 2017-07-28 医疗免疫有限公司 抗体衍生物
PT2635601T (pt) 2010-11-04 2016-09-27 Boehringer Ingelheim Int Anticorpos anti-il-23
GB201100282D0 (en) 2011-01-07 2011-02-23 Ucb Pharma Sa Biological methods
TW201309330A (zh) 2011-01-28 2013-03-01 Abbott Lab 包含糖基化抗體之組合物及其用途
WO2012104402A1 (en) 2011-02-04 2012-08-09 Ab Science Treatment of severe persitent asthma with masitinib
EP4039275A1 (en) 2012-05-03 2022-08-10 Boehringer Ingelheim International GmbH Anti-il-23p19 antibodies
WO2014004436A2 (en) 2012-06-27 2014-01-03 Merck Sharp & Dohme Corp. Crystalline anti-human il-23 antibodies
WO2014149425A1 (en) 2013-03-15 2014-09-25 Amgen Inc. Methods for treating psoriasis using an anti-il-23 antibody
KR20150128859A (ko) 2013-03-15 2015-11-18 암젠 인크 항-il23 항체를 사용하여 크론병을 치료하는 방법
KR20140119396A (ko) 2013-03-29 2014-10-10 삼성전자주식회사 단백질 약물의 액상 제형
BR112017004169A2 (pt) 2014-09-03 2017-12-05 Boehringer Ingelheim Int composto direcionado à il-23a e ao tnf-alfa e usos do mesmo
CN107206081A (zh) 2015-02-04 2017-09-26 勃林格殷格翰国际有限公司 治疗炎性疾病的方法
US10280231B2 (en) 2015-07-23 2019-05-07 Boehringer Ingelheim International Gmbh Compound targeting IL-23A and B-cell activating factor (BAFF) and uses thereof
TWI733695B (zh) 2015-09-18 2021-07-21 德商百靈佳殷格翰國際股份有限公司 治療發炎性疾病之方法

Also Published As

Publication number Publication date
GEP201706733B (en) 2017-09-25
CY2019040I1 (el) 2020-05-29
ES2593754T3 (es) 2016-12-13
EP2635601B1 (en) 2016-07-20
MY162791A (en) 2017-07-14
NL301013I2 (nl) 2020-01-09
PE20141162A1 (es) 2014-09-18
NO2019038I1 (no) 2019-10-17
JP2019054809A (ja) 2019-04-11
EA201300530A1 (ru) 2013-12-30
US9441036B2 (en) 2016-09-13
HRP20161141T1 (hr) 2016-12-02
KR101931591B1 (ko) 2018-12-24
CA3017116A1 (en) 2012-05-10
MA34641B1 (fr) 2013-11-02
CA2816950A1 (en) 2012-05-10
CN103282382B (zh) 2017-11-03
KR102049223B1 (ko) 2019-11-28
AP3953A (en) 2016-12-22
EP3115375A1 (en) 2017-01-11
US8778346B2 (en) 2014-07-15
AU2016273970A1 (en) 2017-01-12
HUE030916T2 (hu) 2017-06-28
ME02499B (me) 2017-02-20
AP2013006820A0 (en) 2013-04-30
EA201890548A1 (ru) 2018-07-31
AU2016273970B2 (en) 2018-06-28
SI2635601T1 (sl) 2017-01-31
JP6445596B2 (ja) 2018-12-26
DK2635601T3 (en) 2016-09-19
US20210198355A1 (en) 2021-07-01
LT2635601T (lt) 2016-10-10
TWI545133B (zh) 2016-08-11
US20120282269A1 (en) 2012-11-08
EA030436B1 (ru) 2018-08-31
LTC2635601I2 (lt) 2021-07-12
PT2635601T (pt) 2016-09-27
LUC00132I2 (hu) 2020-07-16
TWI653242B (zh) 2019-03-11
PL2635601T3 (pl) 2017-02-28
JP2014500009A (ja) 2014-01-09
TW201641516A (zh) 2016-12-01
CO6801628A2 (es) 2013-11-29
US20190144534A1 (en) 2019-05-16
US20140363444A1 (en) 2014-12-11
CN107522784A (zh) 2017-12-29
TW201307386A (zh) 2013-02-16
WO2012061448A1 (en) 2012-05-10
MX343858B (es) 2016-11-25
EP3281954A1 (en) 2018-02-14
AU2011323426A1 (en) 2013-06-06
CY2019040I2 (el) 2020-05-29
MX362039B (es) 2019-01-07
CA2816950C (en) 2018-11-27
CY1118014T1 (el) 2017-05-17
EP2635601A1 (en) 2013-09-11
ECSP13012649A (es) 2013-07-31
JP6126532B2 (ja) 2017-05-10
AU2018236692A1 (en) 2018-10-11
NZ610592A (en) 2015-03-27
SG10201604605VA (en) 2016-07-28
CN103282382A (zh) 2013-09-04
AU2011323426B2 (en) 2016-09-29
AU2018236692C1 (en) 2021-11-04
LTPA2019518I1 (lt) 2019-11-11
BR112013011065B1 (pt) 2022-03-15
JP2017079785A (ja) 2017-05-18
KR20180137588A (ko) 2018-12-27
US10202448B2 (en) 2019-02-12
IL225648A0 (en) 2013-06-27
BR112013011065A2 (pt) 2018-09-25
IL244335A0 (en) 2016-04-21
AR083747A1 (es) 2013-03-20
KR20130139975A (ko) 2013-12-23
IL244335A (en) 2017-11-30
SG190006A1 (en) 2013-06-28
MX2013005015A (es) 2013-08-08
NL301013I1 (hu) 2019-10-22
US20160333091A1 (en) 2016-11-17
CN107522784B (zh) 2021-07-02
IL225648A (en) 2016-04-21
AU2018236692B2 (en) 2020-07-02
RS55161B1 (sr) 2017-01-31
HK1247940A1 (zh) 2018-10-05
LUC00132I1 (hu) 2019-10-16
JP6758361B2 (ja) 2020-09-23
EP3456740A1 (en) 2019-03-20
MX2019000046A (es) 2023-10-05
UY33703A (es) 2012-06-29

Similar Documents

Publication Publication Date Title
HUS1900048I1 (hu) Anti-IL-23 antitestek
HRP20180952T1 (hr) Anti-dll3 antitijelo
ZA201209004B (en) Anti-fgfr2 antibodies
GB201000467D0 (en) Antibodies
IL221371A0 (en) Anti-lrp6 antibodies
HUE040213T2 (hu) Anti-TIM antitest
PL2616489T3 (pl) Przeciwciało anty-huTNFR1
IL225667A0 (en) A new antigen
EP2596022A4 (en) SPECIFIC ANTIBODIES ANTI-HETERODIMER IL-23
HK1194388A1 (zh) 抗缺刻蛋白 抗體
PT2603528T (pt) Anticorpos glicosilados em fab
GB201020738D0 (en) Antibodies
GB201002238D0 (en) Antibodies
ZA201302459B (en) Antibodies
GB201007957D0 (en) Antibody
GB201020751D0 (en) Antibodies
GB201005062D0 (en) Antibodies
GB201017780D0 (en) Antibody